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Summary A method has been developed for measuring the drug sensitivity of human gliomas in short-term
culture, using scintillation counting or autofluorography. Cell cultures prepared from malignant astrocytomas
were treated with anticancer drugs whilst in exponential growth in microtitration plates. After drug treatment
and a recovery period, residual viability was measured by [3H] leucine incorporation followed by scintillation
counting or by [35S] methionine incorporation and autofluorography in situ. In 5 glioma cell lines tested
against 6 drugs, the microtitration method correlated well with monolayer cloning. Although replicate samples
of the same tumour showed little variation in chemosensitivity, there was marked variation between the
chemosensitivities of cultures derived from the tumours of different patients. However, as variability between
replicates was apparent during drug exposure or shortly after, it is important to allow the assay to run as
long as possible after drug removal. It is hoped that this assay may provide the basis of a method for the
prediction of in vivo chemosensitivity or the screening of potential chemotherapeutic drugs.
The growth of human glioma in cell culture offers a
potentially valuable system for assaying the relative
sensitivity of different tumours to antineoplastic
drugs. The objective underlying the present
experiments has been to develop an assay which
will enable the comparison of drug sensitivities in a
large number of different tumours and ultimately
provide enough information on relative sensitivities
to aid in the planning ofchemotherapy.
Previous attempts at predictive drug testing
(Limburg & Heckman, 1968, Knock et al., 1974,
Nissen et al., 1978, Salmon et al., 1978) have relied
on relatively short drug exposures, usually
considerably less than one cell cycle. The results
with HeLa (Freshney et al., 1975) and with glioma
(Morgan & Freshney, 1979) showed that
observations of less than one cell cycle could often
prove misleading. Hence prolonged drug exposure
and recovery periods have been employed. An assay
using microtifration plates has been selected for the
present experiments because it provides a large
number of replicates with low cell numbers and
should be easy to automate. Isotopic labelling gives
a rapid and objective assessment of cytotoxicity and
has been found to be most suited to microtitration
plates. The incorporation of labelled precursors into
protein was selected as being least likely to be
influenced directly by cytostatic drugs while still
registering a reduction in the viability of the cell
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population. Previous results with this type of assay
(Freshney, 1976) indicated a need to record the time
course of the development of cytotoxicity.
Maximum sensitivity was not expressed until after
4-5 cell population doublings, particularly with
antimetabolites.
Although attempts to apply predictive drug
testing to cells from many different types of solid
tumour have often been prevented by the difficulty
in obtaining pure replicating cultures of malignant
cells, cell cultures from human glioma have been
found to be made up predominantly of dividing
aneuploid astrocyte-like cells, which are not
overgrown by stromal fibroblasts.
The response of these cultures to a number of
drugs is reported here in an attempt to compare the
sensitivities of different cell lines in early passage
culture. The selection of drugs was based both on
clinical usage (e.g. procarbazine, CCNU and
vincristine) and on previous indications of
sensitivity in vitro (e.g. 5-fluorouracil, cytosine
arabinoside and vinblastine). The assay is based on
that of Freshney, et al., (1975) with the end point
determined by scintillation counting or, where
specified, scintillation autofluorography (Freshney &
Morgan, 1978, Thomas et al., 1979).
Materials and methods
Media and reagents:
The growth medium used was either Ham's F12 or
FIO supplemented with Eagle's MEM amino acids
(Flow Laboratories), non-essential amino acids
(Flow Laboratories), 50 units ml-' benzyl penicillin,
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50 pgmlP' streptomycin and buffered with 20mM
HEPES and 2% CO2. For collection of samples it
contained penicillin (250 units ml-1), streptomycin
(250ygml-1), kanamycin (100 pgml-) or
gentamycin (50pgmlP1) and amphotericin B
(2.5ygml-1). The medium was supplemented with
20% selected foetal bovine serum for culture and
drug experiments. Dissection and washings were
performed in Hanks' balanced salt solution (HBSS)
containing the same concentration of antibiotics as
in the collection medium (DBSS), but without
sodium bicarbonate and glucose. Collagenase
(Worthington, CLS grade) was made up at a
concentration of 2000 units ml-' in HBSS and
stored frozen at -20°C in aliquots. Drugs used in the
study are given in the Table and were stored at
-20°C until used. Drug breakdown in storage was
not determined but assumed to be minimal at this
temperature and to be consistent between
experiments.
Collection, disaggregation and culture:
All the tumours used were malignant astrocytomas
(Kernohan grades III or IV) confirmed from paraffin
wax section by Dr. D.I. Graham, Department of
Neuropathology, Institute of Neurological Sciences,
Southern General Hospital, Glasgow. Surgical
biopsies were collected into the holding medium
described above. Although satisfactory cultures were
obtained even after 48h storage at 4°C, the culture
was usually initiated within 4h of surgery. The
sample was washed in DBSS, chopped into pieces
of about 1-2 mm and washed twice more by
resuspension and settling in DBSS. The pieces were
finally suspended in 4.5ml culture medium and
transferred to a plastic culture flask (Falcon, 25 cm2
growth area) at 20-50 pieces per flask. Collagenase
(0.5ml) was added to give a final concentration of
200 units ml-1.
After 24-73h in collagenase, disaggregation was
completed by gentle pipetting and the cell
suspension was centrifuged for 10min at 500g to
remove the enzyme. The resulting pellet was
resuspended in 5ml fresh culture medium and
transferred to a new flask. Depending on growth
rate, viability and size of sample, a confluent
monolayer took 1-3 weeks to form. The cells were
then subcultured and used in drug experiments as
secondary or tertiary cultures.
Drug experiments:
Monolayer cultures were trypsinised in exponential
growth phase and 96-well microtitration plates
(Nunclon or Linbro) were seeded to give 103 cells
per well. After 1-3 days, serial dilutions of the drugs
(Table) in culture medium were added to the plates.
One or two wells in each row were left free of drugs
to act as controls. The plates were allowed to
equilibrate with 2% CO2 for 30min and then sealed
with Mylar film (Flow Laboratories) and replaced
at 36.5°C for 3 days. Medium was removed by
suction and the drugs replaced at 24 and 48h. With
most cell lines this corresponded to at least one
population doubling time. In all drug experiments
Table Drugs used in the study
Highest
Chemical Trade Concentration
Name Name Supplier used(mMIl')
Bleomycin (BL) Lundbeck 0.0014
CCNU Lomustine Lundbeck 0.202
Methyl CCNU (Me-CCNU) Semustine National Cancer 0.202
Institute
Cytosine Arabinoside
(Ara-C) Sigma 11.9
5-Fluoro-uracil (5-FU) Sigma 7.69
Mustine HC1 (MU) Mustine Boots 17.3
Procarbazine HCI (PCB) Natulan Roche 4.5
Vinblastine S04 (VB) Velbe Lilly 0.123
Vincristine (VCR) Oncovin Lilly 0.0006
VM26 - Sandoz 0.02CHEMOSENSITIVITY OF ASTROCYTOMA CULTURES 207
cell counts were made of replicate plates of each cell
line to determine population doubling time and to
ensure that the cultures remained in exponential
growth throughout drug treatment and recovery. In
time course experiments, drug exposure periods of
1, 2 and 3 days were employed.
After drug exposure, the monolayer was washed
3 x with fresh medium and the culture continued
("recovery period"). Throughout the recovery period
the medium was replaced at least every 48h. In
time course experiments, a period of 3h recovery
wasg allowed for the equilibration of acid soluble
pools and efflux of unbound drug when labelling
was performed shortly after drug removal.
Sampling by scintillation counting
At intervals during drug exposure and recovery the
growth medium was replaced with medium
containing 20p Ciml-' L-leucine-4, 5-[3H] (specific
activity 10mCi M-1) and incubated for a further
4h. The plates were washed, and cell protein,
solubilized in IN NaOH, counted as previously
described (Freshney et al., 1975). The [3H] leucine
incorporation of each well in a row was expressed
as a percentage of the control in that row and the
dose of drug which inhibited protein synthesis by
50% (ID50) or 90% (ID90) determined.
Sampling by scintillation autofluorography
In later experiments, uptake was determined by
labelling the cultures with [35S] methionine (2-
20pCimlPt, specific activity 15-92 CiM-', 218
Ci M-1 before addition to medium) and adding
scintillation fluid directly to the acid insoluble
residues in the microtitration plate (Freshney &
Morgan 1978). The solvent was dried off by
centrifugation and autofluorograms were prepared
on Kodak RP Royal-X X-ray film at -70°C. The
autofluorograms were analysed densitometrically on
a Helena Autoscanner with a 7 x 2mm slit and
ID50 and ID90 values determined as above.
Cloning
Exponentially-growing cells were treated with drugs
in 25cm2 flasks, the drugs being replaced daily for
3 days. The flasks were then trypsinised and by
determining the number of cells in the control flask
each cell suspension was diluted to give 50-200 cells
ml-'.
The cells were plated out, either alone or
on mitomycin-C treated (2pgml- 1 overnight)
homologous feeder layers in 9cm petri dishes
(Nunclon). These were incubated for 2-3 weeks,
fixed, stained and the colonies counted.
Results
Characterisation ofcultures
Twenty-four anaplastic astrocytomas, all of which
grew well as monolayers, were selected for this
study. Primary cultures of cells with long thin
processes tended to form a network in sub-
confluent cultures, but gave way to polygonal or
spindle-shaped cells after serial passage. Although
karyotypes were not performed on all the lines used,
examination of some, and of many similar lines
derived in the same manner, showed considerable
aneuploidy with modal chromosome numbers
ranging from 40-46 chromosomes (Guner et al.,
1977, Freshney, 1980). Recent evidence has shown
that these cell cultures are capable of growth on
confluent monolayers of normal contact-inhibited
cells, while cells cultured from normal brain are not
(Freshney et al., 1980) and that they have a higher
labelling index with [3H] TdR at terminal cell
density than cultures derived from normal brain
(Morgan & Freshney, 1980).
Derivation ofsensitivity measurements
Percentage inhibition curves displaying the effect of
drug concentration on inhibition of [3H] leucine
incorporation for 5-fluorouracil (5FU), cytosine
arabinoside (Ara-C), mustine (MU) and vinblastine
(VB) were used to derive ID50 values which were
then plotted against time from addition of drug
(Figure 1). Increasing the exposure time reduced
the ID50 and a further decrease was often observed
during continued culture after removal of drug. In
some cases, particularly with 5-FU, a plateau value
was established between 6 and 8 days.
Standard deviations of 4 replicate cultures
exposed to 5-FU and Ara-C were 20% and 16% of
the mean respectively, at the time of drug removal,
and 28% and 43% respectively, at the end of the
assay.
It has been assumed that an exposure period of 3
days allows most of the proliferating cells to pass
through the cell cycle at least once in the presence
of drug. As cycle times are known to vary within
one tumour cell population and between cell lines
from different tumours, some cells will not have
completed a full cycle in the presence of drugs.
However, this is such a small proportion that
adapting the assay to suit such extremes would be
technically unmanageable.
Comparison of ID50 values derived
microtitration assay and clonogenicity
from
A series of experiments was performed with 5 cell
lines and 6 different drugs. The ID50 values were
determined in microtitration plates using208 D. MORGAN et al.
Exposure Recovery
1 2 3 1
10-5 ->I \ 10-6 lo-,o
0~~~~~~~~~~~~
106I \0
1010
10-11
1 2 3 4 5 6 7 8 9
Days after drug addition
Figure 1 Development of ID50 with time. Astrocytoma cells were labelled with [3H] leucine after drug
treatment, incorporation determined by conventional scintillation counting and IDSO values derived from %
inhibition plotted against drug concentration. 5-fluorouracil (5-FU) (0); cytosine arabinoside (Ara-C) (0);
vinblastine (VB) (-); mustine (MU) (U). MU sensitivity was determined on IJK cells; 5-FU, Ara-C and VB on
WMD cells.
scintillation autofluorography after 3 days drug
exposure and 5 days recovery and by cloning the
cells on an homologous mitomycin-C treated feeder
layer immediately after 3 days drug exposure. The
results (shown in Figure 2a) show a high degree of
correlation between the 2 methods, the correlation
coefficient being 0.96 (p<0.001). Two of the points
lying furthest off the regression line belong to GMS,
a cell line found subsequently to contain a mixed
population ofendothelial and glial cells.
A comparison of ID90 values by microtitration
and cloning gave a lower correlation coefficient
(0.82, p<0.001) (Figure 2b). Although the slope of
the regression line was similar, there was greater
scatter and this was not confined to any one cell
line.
When the 5 cell lines were ranked in order of
sensitivity by cloning and microtitration, the only
major discrepancy arose with GMS and VM26
where cloning gave a lower ID50 than
microtitration by 2 orders of magnitude. Any other
alterations in ranking sequence were only due to
minor differences in ID50. Ranking the cell lines by
ID90 however, produced several discrepancies
in keeping with the increased scatter observed in
the regression plot.
Comparison of ID50 time courses in primary,
secondary and tertiary cultures and in multiple
culturesfrom the same biopsy
Assays were performed on 2 cell lines (BRO and
HNY) at different stages of culture (Figure 3).
Microtitration plates were set up (a) directly after
removal of collagenase (primary culture), (b) after
trypsinisation of the primary culture (secondaryCHEMOSENSITIVITY OF ASTROCYTOMA CULTURES 209
culture), and (c) after trypsinisation of the secondary
culture (tertiary culture). These cultures were treated
with 5-FU and MU and their viability determined
by [3H] leucine incorporation and scintillation
counting. Assays done on primary cultures showed
marked oscillations in ID50 with time and did not
conform to the time course predicted by the HeLa
cell model (Freshney et al., 1975). However, the
secondary and tertiary cultures behaved in a more
predictable fashion.
A comparison of replicate cultures and multiple
cultures from the same biopsy also revealed that the
greatest variability occurred during the early stages
of an assay and the possibility exists that there is
some degree of parasynchrony of the cell cycle
induced by transfer prior to the commencement of
a
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the assay. With 5-FU the early variability has gone
by the time drugs are removed at 3 days, but with
some other drugs, particularly vincristine and
nitrosourea it may still persist.
Differences between individual tumours
A series of comparative experiments were
performed, using tertiary cultures, to determine
whether cultures from separate gliomas would
exhibit differing sensitivities. Secondary cultures
were treated with Ara C, 5-FU, VB and MU and
viability was determined by labelling with [3H]
leucine followed by conventional scintillation
counting. There were 5 main features of these
curves (Figure 4 a-d):
ADAO AV7,06
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Figure 2 Correlation of microtitration and clonogenic survival curves. Microtitration plates were labelled
with [35S] methionine, 5 days after removal of drugs, incorporation measured by autofluorography and ID50
(a) and ID90 (b) values derived from the survival curves. Correlation coefficients were 0.96 and 0.82 for (a)
and (b) respectively. In (a) the broken line represents the regression with G-GMS points excluded. (For Figure
2b see overpage).
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1) The ID50 in all cases fell rapidly, although not
always continuously, between 24 and 72h.
2) A low ID50 at 24h was often, but not invariably,
accompanied by a steep gradient in the rate of
change ofID50.
3) A plateau of maximum sensitivity was reached
with 5-FU at 72h.
4) Vinblastine showed the greatest differences in
sensitivity between lines suggesting a division
into 2 groups, one insensitive and the other so
sensitive that the ID50 drops below the
minimum concentration.
5-FU sensitivities were similar by the end of
the assay with the exception of one line that was
apparently resistant. This line had a long
doubling time of 132h. In most cases, however, a
steep slope or low 3-day ID50 value did not
correlate with a short doubling time.
5) Divergence in the curves for Ara-C suggested
that there may have been differences in the rates
at which maximum sensitivity was reached, but
by the time maximum sensitivity was reached the
differences in ID50 had diminished.
JP
Dgo(M) Microtitration
Extrapolation might suggest further convergence
had the assay continued for longer.
Extended series ofcomparative observations
A more extensive series of observations was made
with a different group of 20 tumours using the
drugs procarbazine (PCB), CCNU, methyl-CCNU
(Me-CCNU) and vincristine (VCR). These 4 drugs
are amongst those most frequently used clinically
for human glioma and are among the most effective.
The results of this series are shown in Figure 5 (a-c)
condensed to give the ID50 values after a 24-72h
recovery period at the end of the log phase of
growth, a point reached at different times by
different cultures. Four observations can be made.
1) The sensitivity to PCB was low; no ID50 fell
below the range of the predicted plasma level,
although 3/13 (30%) fell within it.
2) All of the ID50 values for VCR fell below the
predicted plasma concentration. Ten of 16 were
closely grouped between 10- " M and
2 x l0-9 M, while the remaining 6 (38%) showedCHEMOSENSITIVITY OF ASTROCYTOMA CULTURES 211
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Figure 3 Development of ID50 values from primary (X); secondary (0); tertiary (0) cultures of 2 cell lines
(BRO and HNY). Viability was determined by [3H] leucine incorporation determined by scintillation
counting.
higher sensitivities between 10-14 M and
10-11 M. Time course data (not shown)
suggested that these six ID50 values were stable.
3) Although 4/13 (31%) of nitrosourea estimations
fell below the predicted plasma level, the
majority registered no measurable ID50 by the
end of the assay. Two of the 4 samples which did
not show a measurable ID50 had been sampled
earlier than the others because cell proliferation
was approaching density limitation. An
extrapolation of the time course of the
development of sensitivity (data not shown)
indicated ID50 values for these 2 examples,
above the threshold of the assay 3 days after
drug removal. This effectively reduces the
number of sensitive samples to 2/13 (15%).
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Figure 4 Time courses of the development of sensitivity to ara-C (a), 5-FU (b). VB (c), and MU (d) by 15
different early passage cell lines derived from different astrocytomas. Viability was determined by [3H]
incorporation and conventional scintillation counting. Arrows indicate points which fall below axes.
4) Five cultures giving ID50 values for nitrosourea
above the threshold by the end of the assay had
shown low ID50 values (10 -1_0-I M)
immediately after exposure to the drug (data not
shown). This suggests that the effect of the drug
on these cultures was transitory and resistance
was readily achieved.
Discussion
The examination of replicate cultures suggests that
the internal variation of the microtitration assay
can be minimised by sampling 3-5 days after drug
removal. With most cell lines this allows for at least
one complete cell cycle in the absence of drugs,
given that the average population doubling time for
these cultures is about 36h and the cell cycle time
of each line will vary around that figure. It was
shown previously with HeLa cells (Freshney, 1976)
that prolonged exposure to drugs and recovery
were necessary to obtain a measurable and stable
ID50 value for many drugs particularly those which
are phase-specific. Present results indicate that
stable ID50 values for several drugs can be
demonstrated with cultures from human glioma, butCHEMOSENSITIVITY OF ASTROCYTOMA CULTURES 213
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Figure 5 Sensitivities of 20 different astrocytomas to
PCB (a), VCR (b) and a nitrosourea (c). Viability was
determined by [35S] methionine incorporation followed
by autofluorography and ID50 values were determined
densitometrically. Each point represents the terminal
ID50 values measured at the end of the recovery
period. Solid symbols in (c) are Me CCNU and open
symbols CCNU. The bars indicate approximate peak
plasma levels attainable in man are taken from
published data by Alberts & Chen (1980) VCR and
nitrosoureas (using values for BCNU) and Schwartz &
Kessler (1967 unpublished) for PCB.
that many samples are still resistant particularly to
nitrosoureas, even after prolonged exposure and
recovery (see below). There is no evidence for
differences in the sensitivity of multiple cultures
from different parts of the same biopsy. This does
not mean that differences do not exist but that
variant populations must represent a small
component of the total population.
The selection of a microtitration plate assay for this
series of measurements was influenced by difficulties
in obtaining reasonable plating efficiencies for a
clonogenic assay. However, the selection of the
appropriate CO2 tension (2%), use of
glucocorticoids in the medium (Guner et al., 1977)
and cloning on homologous feeder layers (Freshney
et al., 1980) have enabled cloning efficiencies from
5%-20% to be achieved, making a clonogenic assay
more feasible. Even though the 2 assays have been
shown to agree, the microtitration assay is quicker
and more adaptable to automated handling and
analysis. Although correlation of the ID50 values is
very good some discrepancies between
microtitration and cloning can be seen when ID90
values are compared. This may reflect the greater
sensitivity of the clonogenic assay in detecting a
small resistant fraction (_5%) which would not be
detectable in the microtitration assay using
autofluorography. Nevertheless, the ability of the
microtitration method to process a large number of
samples in a semi-automated manner and provide
gross sensitivity data comparable to clonogenic
survival curves, makes it a very valuable technique
for rapid screening. The interpretation of a
clonogenic assay is usually straightforward as it is
based on counting surviving colonies of cells. To be
equivalent the ID50 at the end of the microtitration
assay should be used and the assay continued for
the maximum culture period possible before density
limitation of growth is apparent.
With the microtitration assay, cultures are
usually available for testing_ within 3 weeks of
surgery and with an assay taking 10-14 days to
perform, a result is available within 4-5 weeks of
operation. Currently patients who are to receive
chemotherapy for cerebral glioma at the National
Hospital do so after completion of radiotherapy-
usually a minimum of 7-10 weeks after operation.
Using a cloning assay where cells are treated in
secondary culture with drugs for 3 days and then
cloned, it might be difficult to obtain a result within
6-7 weeks of operation.
The acceptance of one parameter rather than
another to predict drug sensitivity in vivo will be
governed by which value correlates best with the
clinical outcome. Preliminary data on a small
number of patients suggest that there is an
interesting correlation between in vitro data and
clinical response (Darling & Thomas, 1981). In 6
patients with malignant glioma treated with PCB,
CCNU and VCR following radiotherapy, three
responded. Two of these patients responded in vitro
to all 3 drugs and 1 responded to 2 of the 3 drugs.
Of the 3 patients who failed to respond clinically,
only 1 had a significant response in vitro. This work
will be reported fully later.
The majority of samples treated with nitrosourea,
VCR or PCB were insensitive. This is also apparent
in the clinical treatment of glioma since varying
degrees of remission still invariably give way to
relapse. There is an indication of low frequency
response rate in these studies (15% for VCR, 20%
for PCB and 7% for nitrosourea) which, though
difficult to evaluate statistically, is of the correct
order of magnitude for the anticipated clinical
response rate to chemotherapy. Perhaps the most
interesting drugs in this survey were the Vinca
alkaloids, since they alone produced persistent
sensitivity, the sensitive samples falling into a
separate and readily distinguishable group. This
would perhaps be the best drug to test for clinical
correlation. Sensitivity to PCB and nitrosourea was
generally poor and showed little evidence of a
permanent effect with most cultures. The low levels
lg-81
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of sensitivity to PCB may have been due to the lack
of generation of the more active metabolites
produced in vivo. The nitrosoureas do not normally
require metabolic activation. The poor response
encountered with them may relate to the
observation that high density non-cycling
populations are often more sensitive to nitrosourea
(Barranco et al., 1973). Limitations in the
microtitration assay makes this difficult to assess
but attempts are being made to investigate this with
the clonogenic assay.
It is unfortunate that some of the more effective
drugs in this series of experiments, e.g. 5-FU, BL
and Ara-C have not been found clinically useful.
Presumably this reflects pharmacokinetic problems,
principally access to tumour sites in the brain.
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